137 related articles for article (PubMed ID: 26414667)
21. [The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients].
Wei JF; Chen GH; Qiu HY; Fu CC; Ding ZX; Liu H; Feng YF; Chen SN; Chang WR; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):304-7. PubMed ID: 21729597
[TBL] [Abstract][Full Text] [Related]
22. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
23. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
[TBL] [Abstract][Full Text] [Related]
24. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
Chou WC; Chou SC; Liu CY; Chen CY; Hou HA; Kuo YY; Lee MC; Ko BS; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo YY; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
Blood; 2011 Oct; 118(14):3803-10. PubMed ID: 21828143
[TBL] [Abstract][Full Text] [Related]
25.
Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
[No Abstract] [Full Text] [Related]
26. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
27. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
Nibourel O; Kosmider O; Cheok M; Boissel N; Renneville A; Philippe N; Dombret H; Dreyfus F; Quesnel B; Geffroy S; Quentin S; Roche-Lestienne C; Cayuela JM; Roumier C; Fenaux P; Vainchenker W; Bernard OA; Soulier J; Fontenay M; Preudhomme C
Blood; 2010 Aug; 116(7):1132-5. PubMed ID: 20489055
[TBL] [Abstract][Full Text] [Related]
28. Low expression of TET2 gene in pediatric acute lymphoblastic leukemia is associated with poor clinical outcome.
Zhang P; Weng WW; Chen P; Zhang Y; Ruan JF; Ba DD; Xu WQ; Tang YM
Int J Lab Hematol; 2019 Oct; 41(5):702-709. PubMed ID: 31441600
[TBL] [Abstract][Full Text] [Related]
29. TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population.
Yao H; Duan M; Lin L; Wu C; Fu X; Wang H; Guo L; Chen W; Huang L; Liu D; Rao R; Wang S; Ding Y
Oncotarget; 2017 Mar; 8(11):18337-18347. PubMed ID: 28407691
[TBL] [Abstract][Full Text] [Related]
30. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
Mohamed AM; Balsat M; Koering C; Maucort-Boulch D; Boissel N; Payen-Gay L; Cheok M; Mortada H; Auboeuf D; Pinatel C; El-Hamri M; Tigaud I; Hayette S; Dumontet C; Cros E; Flandrin-Gresta P; Nibourel O; Preudhomme C; Thomas X; Nicolini FE; Solly F; Guyotat D; Campos L; Michallet M; Ceraulo A; Mortreux F; Wattel E
Leuk Res; 2017 May; 56():21-28. PubMed ID: 28167452
[TBL] [Abstract][Full Text] [Related]
31. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
[TBL] [Abstract][Full Text] [Related]
32. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
[TBL] [Abstract][Full Text] [Related]
33. [Clinical significance of TET2 gene expression in 157 adult acute myeloid leukemia patients with normal cytogenetics].
Zhu Z; Chen J; Yu M; Chen F; Chen Z; Lou J; Tong H; Huang J; Qian W; Meng H; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):802-7. PubMed ID: 25246247
[TBL] [Abstract][Full Text] [Related]
34. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
35. Detection of TET2 Mutation in Patients with De Novo Acute Myeloid Leukemia: A Mutation Analysis of 51 Iranian Patients.
Chehreghani Z; Sadeghian MH; Ayatollahi H; Bagheri P; Zafari Z; Rezazadeh O; Arbab Jafari P
Asian Pac J Cancer Prev; 2022 Mar; 23(3):803-806. PubMed ID: 35345350
[TBL] [Abstract][Full Text] [Related]
36. TET2 mutations in acute myeloid leukemia: a comprehensive study in patients of Sindh, Pakistan.
Shaikh ARK; Ujjan I; Irfan M; Naz A; Shamsi T; Khan MTM; Shakeel M
PeerJ; 2021; 9():e10678. PubMed ID: 33643703
[TBL] [Abstract][Full Text] [Related]
37. Clinical implications of novel mutations in epigenetic modifiers in AML.
Abdel-Wahab O; Patel J; Levine RL
Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
[TBL] [Abstract][Full Text] [Related]
38. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.
Soura EN; Karikas GA
J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775
[TBL] [Abstract][Full Text] [Related]
39. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
Bacher U; Haferlach C; Schnittger S; Kohlmann A; Kern W; Haferlach T
Ann Hematol; 2010 Jul; 89(7):643-52. PubMed ID: 20195608
[TBL] [Abstract][Full Text] [Related]
40. The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia.
Nabil R; Hassan NM; Abdellateif MS; Gawdat RM; Elshazly SS
Mol Biol Rep; 2023 Jan; 50(1):641-653. PubMed ID: 36371552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
